Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice

Derek Weycker1 Xiaoyan Li2 Gail DeVecchis Wygant2 Theodore Lee3 Melissa Hamilton2 Xuemei Luo4 Lien Vo2 Jack Mardekian3 Xianying Pan5 Leah Burns2 Mark Atwood1 Ahuva Hanau1 Alexander T. Cohen6

1 Policy Analysis Inc. (PAI), Brookline, Massachusetts, United States
2 Bristol-Myers Squibb, Lawrenceville, New Jersey, United States
3 Pfizer Inc., New York, New York, United States
4 Pfizer Inc., Groton, Connecticut, United States
5 Bristol-Myers Squibb, Wallingford, Connecticut, United States
6 Guy’s and St. Thomas’ Hospitals, London, United Kingdom

Address for correspondence Derek Weycker, PhD, Policy Analysis Inc. (PAI), Four Davis Court, Brookline, Massachusetts, 02445, United States (e-mail: dweycker@pai2.com).

ERRATUM

The authors have brought to the publisher’s attention that there were some errors in ►Fig. 1 of the article and ►Table 1 of the Supplementary Material published in the above article in Thrombosis and Haemostasis, Volume 118, Number 8, 2018 (DOI: 10.1055/s-0038-1673689). The corrected figure and table appear as follows:
Fig. 1 Selection of patients receiving apixaban or warfarin as outpatient therapy for VTE. IVCF, inferior vena cava filter; OAC, oral anticoagulant; PAC, parenteral anticoagulant; VTE, venous thromboembolism.
### Table 1
Selection of patients receiving apixaban or warfarin as outpatient therapy for VTE

<table>
<thead>
<tr>
<th>Condition/Exclusion Criteria</th>
<th>Optum (n [%])</th>
<th>Total Population (n [%])</th>
<th>MarketScan (n [%])</th>
<th>PharMetrics (n [%])</th>
<th>Humana (n [%])</th>
<th>Other (n [%])</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion Criteria: A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnosis:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnosis of PE (with or without DVT)</td>
<td>66,428 (30.0%)</td>
<td>110,436 (29.1%)</td>
<td>96,415 (30.1%)</td>
<td>132,802 (28.6%)</td>
<td>406,081 (29.3%)</td>
<td></td>
</tr>
<tr>
<td>Exclusion criteria:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnosis:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnosis of PE (with or without DVT)</td>
<td>66,428 (30.0%)</td>
<td>110,436 (29.1%)</td>
<td>96,415 (30.1%)</td>
<td>132,802 (28.6%)</td>
<td>406,081 (29.3%)</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**
- *Other than non-melanoma skin cancer*
- Prophylactic use of OAC/PAC will be determined based on duration and timing of use (See Appendix B)
- "Incidental" use of apixaban or warfarin will be determined by the use of OAC/PAC without evidence of a recent VTE event (See Appendix B)

\[\text{Diagnosis of PE (with or without DVT)}\]

**Thrombosis and Haemostasis**

Erratum

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.